Approval · Notice of Compliance 16099 · 2014
EDURANT: Notice of Compliance 16099
Issued September 8, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16099
- Date
- September 8, 2014
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- This snds submission was to update the product monograph with respect to information in the drug interactions section
- Therapeutic class
- Human immunodeficiency virus (hiv) non-nucleoside reverse transcriptase inhibtor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EDURANT | 02370603 | Marketed |
Medicinal ingredients
- RILPIVIRINE HYDROCHLORIDE 25 MG per TAB